89zr-dfo-fianlimab - a radioimmunoconjugate consisting of fianlimab, a human monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (lag-3; lag3; cd223), linked, via the chelator desferrioxamine (dfo), to the positron-emitting radionuclide zirconium zr 89 (zr89), with potential use as an imaging agent upon positron emission tomography (pet) imaging. Upon administration of zirconium zr 89-dfo- fianlimab, the fianlimab moiety specifically targets and binds to lag-3. Upon binding, the radioisotope moiety may be detected using pet, thereby allowing the imaging and quantification of lag-3-expressing tumor infiltrating lymphocytes (tils). Lag-3, a member of the immunoglobulin superfamily (igsf), is expressed on various immune cells; its expression on tils is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and t-cell activation. Also see zirconium zr 89-dfo-fianlimab
Up to date info
Latest research - 89zr-dfo-fianlimab
|This medical article is a stub. You can help WikiMD by expanding it.|
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 89zr-dfo-fianlimab for any updates.